Trump Orders 100% Tariffs on Patented Drug Imports, Restructures Metal Duties

Tariffs are taxes imposed on imported goods, primarily used to protect domestic industries, generate revenue, or exert leverage in international trade negotiations. Historically, U. S.

trade policy has fluctuated between protectionism and free trade, with recent administrations showing a greater inclination towards tariffs to address perceived trade imbalances or unfair practices.

The pharmaceutical industry, with its complex global supply chains and high research and development costs for patented drugs, is particularly sensitive to trade policy changes. Donald Trump's order for up to 100% tariffs on patented drug imports represents a significant escalation of his 'America First' trade agenda. This aggressive measure targets intellectual property in the pharmaceutical sector, aiming to compel drug manufacturers to produce more within the U. S. and potentially force down prices for patented medications. Concurrently, the restructuring of metal duties indicates a broader protectionist strategy across key industrial sectors, potentially leading to higher costs for some U. S. industries reliant on imported metals. These tariffs carry substantial implications for global trade, particularly for the pharmaceutical and manufacturing sectors. While the direct impact on India's predominantly generic drug exports may be limited, the policy sets a precedent for protectionist measures that could affect global intellectual property rights and trade agreements. For competitive exams, understanding the economic rationale and consequences of tariffs, their impact on global supply chains, and the strategic trade policies of major economies are crucial for international trade and economic governance modules.